Allergan begins trials on hair-growth drug
Drugmaker Allergan is recruiting volunteers for clinical trials of a hair-growth treatment based on the active ingredient in Latisse (bimatoprost ophthalmic solution, 0.03 percent), the company’s eyelash-growth treatment. (Source: Modern Medicine)
Read more here:
Allergan begins trials on hair-growth drug
Latisse gains popularity among those seeking longer, fuller lashes
St. Louis — As women become more familiar and comfortable with the idea of a medication that can help give them the kind of lush, long eyelashes they’ve always wanted, physicians have increasingly found themselves prescribing Latisse (bimatoprost ophthalmic solution 0.03 percent, Allergan) and addressing eyelash issues previously dealt with primarily at the cosmetics counter. (Source: Modern Medicine)
Visit link:
Latisse gains popularity among those seeking longer, fuller lashes
(sponsored multimedia) Latisse™ (bimatoprost ophthalmic solution) 0.03%: A National Summit on New Aesthetic Opportunities
(Source: Modern Medicine)
